GlassScriptPhysician profile
Micheal Moisant
NPI 1063463800
$1,645.11
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $188 · 2021: $246.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $276.86 | 2019-2021 | |
| Lilly USA, LLC | $274.78 | 2019-2020 | |
| Novo Nordisk INC | $244.27 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $160.73 | 2019-2021 | |
| Glaxosmithkline, LLC. | $107.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.15 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $78.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $59.41 | 2019 | |
| Neos Therapeutics, LP | $51.82 | 2021 | |
| Pfizer INC. | $51.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.39 | 2019-2021 | |
| Amarin Pharma, INC. | $48.72 | 2021 | |
| Genentech USA, INC. | $46.46 | 2019-2020 | |
| Amgen INC. | $26.23 | 2019 | |
| Mylan Specialty L.P. | $19.04 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $16.02 | 2021 | |
| Abbvie INC. | $14.72 | 2021 | |
| Seqirus USA INC | $13.02 | 2021 | |
| Adlon Therapeutics L.P. | $13.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micheal Moisant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.